Vaccination with cationic liposome-encapsulated CD4 and CD8 T cell neoepitopes induces superior tumor control
Source abstract
Abstract
Therapeutic cancer vaccines represent a promising new development in the field of cancer immunotherapy, aiming to elicit T cell responses targeting tumor antigens. Cancer vaccines consisting of multiple tumor-specific T cell peptide epitopes require optimal formulation, as peptides by themself are poorly immunogenic. In this study, we report the development of a novel multi-epitope cationic liposomal cancer vaccine utilizing real neoepitopes and evaluated the efficacy in a murine colorectal cancer model for personalized vaccination. MHC class I and class II neoepitope peptides were successfully individually encapsulated into cationic liposomes. Upon intradermal vaccination significantly higher neoepitope-specific CD8 and CD4 T cells were induced, compared to vaccination with soluble peptides or peptides mixed with empty liposomes. Moreover, this liposomal neoepitope vaccine was highly effective in preventing MC38 tumor outgrowth and cured 60% of mice bearing a lethal tumor. In conclusion, this study shows that cationic liposomal multi-epitope peptide formulations are a promising strategy for personalized cancer immunotherapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Immunotherapy and Immune Responses · vaccines and immunoinformatics approaches · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (51)
Show source-provided references
1. Cancer vaccines: the next immunotherapy frontier10.1038/s43018-022-00418-6 ↗
2. Recent advances in therapeutic cancer vaccines10.1038/s41568-025-00820-z ↗
3. Neoantigens in cancer immunotherapy10.1126/science.aaa4971 ↗
4. Personalized vaccines for cancer immunotherapy10.1126/science.aar7112 ↗
5. Eliciting antitumor immunity via therapeutic cancer vaccines10.1038/s41423-025-01316-4 ↗
6. An immunogenic personal neoantigen vaccine for patients with melanoma10.1038/nature22991 ↗
7. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial10.1038/s41586-018-0792-9 ↗
8. Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions10.1136/jitc-2022-005016 ↗
9. More than one reason to rethink the use of peptides in vaccine design10.1038/nrd2224 ↗
10. Beyond just peptide antigens: the complex world of peptide-based cancer vaccines10.3389/fimmu.2021.696791 ↗
11. Efficient eradication of established tumors in mice with cationic liposome-based synthetic long-peptide vaccines10.1158/2326-6066.CIR-16-0283 ↗
12. Cationic liposomes: a flexible vaccine delivery system for physicochemically diverse antigenic peptides10.1007/s11095-018-2490-6 ↗
13. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients10.1158/1078-0432.CCR-12-2189 ↗
14. Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication10.1186/s40425-018-0455-2 ↗
15. Effectiveness of combination therapy with ISA101 vaccine for the treatment of human papillomavirus-induced cervical cancer10.3389/fonc.2022.990877 ↗
16. Peptide-based therapeutic cancer vaccine: current trends in clinical application10.1111/cpr.13025 ↗
17. Safety and tolerability evaluation of the use of Montanide ISA51 as vaccine adjuvant: a systematic review10.1080/21645515.2015.1071455 ↗
18. Hollow microneedle-mediated micro-injections of a liposomal HPV E7(43-63) synthetic long peptide vaccine for efficient induction of cytotoxic and T-helper responses10.1016/j.jconrel.2017.11.035 ↗
19. Effective antitumor peptide vaccines can induce severe autoimmune pathology10.18632/oncotarget.19688 ↗
20. Shared epitopes create safety and efficacy concerns in several cancer vaccines10.1136/jitc-2025-012217 ↗
21. Identification of a neo-epitope dominating endogenous CD8 T cell responses to MC-38 colorectal cancer
22. Mutant MHC class II epitopes drive therapeutic immune responses to cancer10.1038/nature14426 ↗
23. Cancer-specific T helper shared and neo-epitopes uncovered by expression of the MHC class II master regulator CIITA10.1016/j.celrep.2022.111680 ↗
24. MC38 colorectal tumor cell lines from two different sources display substantial differences in transcriptome, mutanome and neoantigen expression10.3389/fimmu.2023.1102282 ↗
25. Neoantigen-specific T cell help outperforms non-specific help in multi-antigen DNA vaccination against cancer
26. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing10.1038/nature14001 ↗
27. Regulation and impact of tumor-specific CD4(+) T cells in cancer and immunotherapy10.1016/j.it.2024.02.005 ↗
28. Linked CD4+/CD8+ T cell neoantigen vaccination overcomes immune checkpoint blockade resistance and enables tumor regression10.1172/JCI164258 ↗
29. CD4(+) T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy10.1136/jitc-2021-004022 ↗
30. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors10.1084/jem.187.5.693 ↗
31. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes10.4049/jimmunol.176.12.7335 ↗
32. Cationic nanoparticle-based cancer vaccines10.3390/pharmaceutics13050596 ↗
33. Cationic liposomes loaded with a synthetic long peptide and poly(I:C): a defined adjuvanted vaccine for induction of antigen-specific T cell cytotoxicity10.1208/s12248-014-9686-4 ↗
34. Induction of CD8+ T-cell responses against subunit antigens by the novel cationic liposomal CAF09 adjuvant10.1016/j.vaccine.2014.05.050 ↗
35. Liposome-based adjuvants for subunit vaccines: formulation strategies for subunit antigens and immunostimulators10.3390/pharmaceutics8010007 ↗
36. Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens10.1038/s41587-019-0390-x ↗
37. Synthetic high-density lipoprotein nanodisks for targeted withalongolide delivery to adrenocortical carcinoma10.2147/IJN.S140591 ↗
38. Designer vaccine nanodiscs for personalized cancer immunotherapy10.1038/nmat4822 ↗
39. Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy10.1172/jci.insight.124507 ↗
40. Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment10.1038/s41598-022-07153-z ↗
41. Cancer vaccines as promising immuno-therapeutics: platforms and current progress10.1186/s13045-022-01247-x ↗
42. Neoantigen-based mRNA vaccine exhibits superior anti-tumor activity compared to synthetic long peptides in an in vivo lung carcinoma model10.1007/s00262-025-03992-7 ↗
43. Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity10.1126/sciadv.adn9961 ↗
44. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer10.1038/s41586-023-06063-y ↗
45. RNA neoantigen vaccines prime long-lived CD8(+) T cells in pancreatic cancer10.1038/s41586-024-08508-4 ↗
46. Low antigen dose in adjuvant-based vaccination selectively induces CD4 T cells with enhanced functional avidity and protective efficacy10.4049/jimmunol.1600965 ↗
47. Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy10.1038/s41586-024-07752-y ↗
48. Concurrent interaction of DCs with CD4(+) and CD8(+) T cells improves secondary CTL expansion: it takes three to tango10.1002/eji.201444477 ↗
49. CD4+ T cell help selectively enhances high-avidity tumor antigen-specific CD8+ T cells10.4049/jimmunol.1401571 ↗
50. Quantification of lipid and peptide content in antigenic peptide-loaded liposome formulations by reversed-phase UPLC using UV absorbance and evaporative light scattering detection10.1016/j.xphs.2022.01.021 ↗
51. Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures10.1084/jem.185.2.317 ↗